Hypertension Diagnostics, Inc. (HDII)
Hypertension Diagnostics, Inc. operates in the Shell Companies industry of the Financial Services sector, headquartered in Richmond Hill, ON, CA. The stock last traded at $0.00, up 0.00% on the session, giving a market capitalisation of $13,681. On trailing twelve-month figures it carries a trailing P/E of -0.25, a net margin of 0.0%. Its beta of -53.23 implies it has historically moved less than the broad market.
Hypertension Diagnostics, Inc. (HDII) is a company that designs, develops, manufactures, and commercializes its own innovative, non-invasive medical technologies. These devices are engineered to identify minute changes in the flexibility of arteries, serving both domestic and international markets. Central to their offerings is the CVProfilor, a system designed for non-invasive assessment of both large and small artery elasticity. The elasticity of small arteries is especially critical, serving as the earliest and most sensitive indicator of cardiovascular disease. The product suite includes the CVProfilor DO-2020, which delivers essential arterial elasticity indices, aiding in the diagnosis of underlying vascular conditions. Its counterpart, the CVProfilor MD-3000, offers precise and specific insights into the presence of blood vessel disease. For scientific study, the HD/PulseWave CR-2000 is a specialized cardiovascular profiling system, equipping scientists and investigators with a non-intrusive method to evaluate arterial elasticity across diverse human research domains. These devices operate by capturing 30 seconds of blood pressure waveform data, subsequently analyzing the digitized patterns to generate a comprehensive CVProfile report. This report details crucial metrics including blood pressure, heart rate, pulse pressure, body surface area, body mass index, and indices for both C1 (large) and C2 (small) artery elasticity. HDII caters to a broad spectrum of clients, including general practitioners, cardiologists, various healthcare practitioners, skilled medical staff, academic and government research scientists, cardiovascular specialists, and pharmaceutical companies. In the U.S., sales are facilitated by a dedicated network of representatives. Established in 1988, Hypertension Diagnostics, Inc. maintains its headquarters in Richmond Hill, Canada.
Hypertension Diagnostics, Inc. is most often compared with the following Financial Services names: